Petros Grivas Highlights Promising TAR-200 Results in Cisplatin-Ineligible MIBC
Petros Grivas, Clinical Director of the GU Cancer Program at the University of Washington, shared a post by Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, on X about a paper by Andrea Necchi et al. published on The Lancet:
“Agree with Shilpa Gupta kudos to my colleague Sarah P. Psutka, UW Urology and Friend Andrea Necchi for leading this trial with colleagues Felix Guerrero-Ramos, Tom Powles et al. Awaiting regulatory review of TAR200 in NMIBC, its role in MIBC merits further investigation!”
Quoting Shilpa Gupta’s post:
“Congrats Andrea Necchi, Sarah P. Psutka, Felix Guerrero-Ramos and entire SunRise-4 team on the very promising results! Exciting to see promising options for cisplatin-ineligible MIBC patients.”
Title: TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial
Authors: Andrea Necchi, Félix Guerrero-Ramos, Paul L. Crispen, Bernardo Herrera-Imbroda, Rohan Garje, Thomas Powles, Charles C. Peyton, Benjamin Pradere, Ja Hyeon Ku, Neal Shore, Martin Bögemann, Mark A. Preston, Evanguelos Xylinas, Cristina Sanchez de Llano, Mohamad Hasan, Hind Stitou, Sumeet Bhanvadia, Hussein Sweiti, Sarah P. Psutka
Read the full article.
More posts featuring Petros Grivas and Shilpa Gupta on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023